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Molecular mechanisms in the brain are assumed to cause the symptoms and severity
of neuropsychiatric disorders. This review concerns the elusive nature of relationships
between the severity of depressive disorders and neuromolecular processes studied
by positron emission tomography (PET). Recent PET studies of human depression have
focused on serotonergic, dopaminergic, muscarinic, nicotinic, and GABAergic receptors,
as well as central processes dependent on monoamine oxidase, phosphodiesterase type
4, amyloid plaques, neurofibrillar tangles, and P-glycoprotein. We find that reliable causal
links between neuromolecular mechanisms and relief from depressive disorders have yet
to be convincingly demonstrated.This situation may contribute to the currently limited use
of PET for exploring the neuropathways that are currently viewed as being responsible for
beneficial effects of antidepressant treatment regimes.
Keywords: depressive disorders, symptom severity, negative emotions, positron emission tomography, brain
imaging, neurobiology, neurotransmitters, reliability
Depressive disorders continue to attract much attention due to
their detrimental impact on individuals and societies (Green-
berg et al., 2003; McIntyre and O’Donovan, 2004; Paykel et al.,
2005). Clearly, we need more effective therapeutic procedures to
alleviate the disabling symptoms of depressive disorders. Much
research has, therefore, been directed toward achieving that goal.
Our interest here relates to the common notion that changes
in the severity of depression are caused by changes in underly-
ing neuromolecular mechanisms. In particular, much research
in brain scanning by positron emission tomography (PET) has
focused over the years primarily on neuroreceptors and neuronal
transporter mechanisms in depressive disorders.
Positron emission tomography imaging differs from other
imaging procedures by determining the dynamics of molecular
processes as they occur in the living organism (Lammertsma, 2002;
Laruelle et al., 2002). PET imaging uses molecules that are radi-
olabeled with a relatively short-lived positron-emitting nuclide.
They are injected into the bloodstream so that the PET scanner
can provide a digital record of the time and place of the radio-
labeled molecule in the organ of interest, in this case the brain.
PET brain imaging is currently used for studying neuromolecular
processes in humans as well as laboratory animals (Bender et al.,
2004; Smith and Jakobsen, 2007; Smith et al., 2007, 2009).
Previously, we described several challenges currently faced by
PET research of depressive disorders (Smith and Jakobsen, 2009;
Smith and Miller, 2010). In general, they resemble challenges
described in a recent report on elusive relationships between neu-
robiology and symptoms in schizophrenia (Mathalon and Ford,
2012). One reason for the challenges stems from the fact that
schizophrenia and depression are both heterogeneous conditions.
Major symptoms of depression include hopelessness, sleep distur-
bance, altered appetite, lack of energy, concentration difficulties,
low self-esteem, self-destructive behavior, painful bodily sensa-
tions, and suicidal ideation, with symptoms and severity differing
from person-to-person. The complex nature of depression surely
warns against viewing it as a single disease with a single neuromol-
ecular cause that can be identified by a single PET scan with a single
radioligand selective for a single synaptic transporter or receptor
(Jones and Rabiner, 2012). Our interest in PET studies of depres-
sive disorders has, nonetheless, induced us to prepare this account
of recently published reports (Table 1), with special attention to
the question of whether reliable relationships have been demon-
strated between neuromolecular events and changes in depression
severity. We hope that the seemingly negative findings can motivate
searches in new directions using PET imaging to identify causal
neuromolecular mechanisms for relief from depressive disorders.
PET RADIOLIGAND BINDING
The basic molecular tools for PET studies are typically syn-
thetic compounds radiolabeled with positron-emitting nuclides
(Figure 1). PET radioligands travel throughout the body via the
bloodstream, enter the brain, and bind to target macromolecules.
The status of neuroreceptors is typically described in terms of the
magnitude with which they bind the PET radioligand, expressed
as binding potential or distribution volume (Innis et al., 2007).
It is important to realize that PET estimates of receptor binding
are a combination of three factors, namely (i) the number of neu-
roreceptors in a molecular conformation suited for binding, (ii)
the affinity of the neuroreceptors for the radiopharmaceutical, and
(iii) the concentration of endogenous neurotransmitter nearby the
neuroreceptors. Thus, differences between depressed subjects and
non-depressed subjects in receptor binding results in most stud-
ies from an unknown combination of pharmacodynamic factors
(Laruelle, 2000; Lammertsma, 2002; Gjedde et al., 2005), which
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must be kept in mind in order to avoid erroneous interpretations
of PET findings on neuroreceptors.
MONOAMINERGIC MECHANISMS
SEROTONIN SYNTHESIS
Disturbances in serotonin synthesis have often been assumed
to contribute to depressive disorders. In a recent study, Frey
et al. (2010) used α-[11C]MTrp to estimate the rate of sero-
tonin synthesis in medication-free, depressed subjects, and in
non-depressed, healthy controls. They hypothesized that sex dif-
ferences in serotonin synthesis may underlay the well-known
overrepresentation of females in lifetime likelihood of depressive
disorders. Strict exclusion criteria were applied to obtain a sam-
ple of currently depressed, drug-free patients for comparison with
age- and sex-matched PET data from healthy subjects retrieved
from a database. Statistical analysis was carried out on nor-
malized parametric images of the brain trapping constant for
α-[11C]MTrp. They found that accumulation of the radioli-
gand in selected brain regions was relatively high in medication-
free, depressed females compared with medication-free, depressed
males. Frey and coworkers postulated that greater disturbances
of serotonin synthesis and serotonergic neurotransmission are
required in males than in females for the occurrence of depres-
sion. Their notion is, however, opposed by the outcome of a study
FIGURE 1 | Continued
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FIGURE 1 | Structural drawings of PET radioligands cited in the present review on depressive disorders.
carried out previously by members of their research group (Rosa-
Neto et al., 2004), in which the clinical severity of depression failed
to correlate with the relative rate of serotonin synthesis in either
males or females. In other studies, tryptophan depletion has been
used to disrupt serotonin synthesis in males and females, but no
consistent sex differences in plasma levels of the serotonin precur-
sor, behavioral responses, or regional binding by serotonin uptake
sites have been found (Moreno et al., 1999; Praschak-Rieder et al.,
2005). Thus, little evidence supports the notion that sex differences
in serotonin synthesis are causally related to either the likelihood
or the severity of depressive disorders.
SEROTONIN TRANSPORT
Serotonin transport has received much attention over the years in
PET studies of depressive disorders (Brust et al., 1999; Smith, 1999;
Cannon et al., 2007; Meyer, 2007). Two factors have contributed
strongly to such studies. Firstly, many antidepressant drugs are
believe to exert their therapeutic effects by binding to the serotonin
transporter and thereby preventing the removal of serotonin from
the synaptic cleft (Meltzer and Lowy, 1987; Hirschfeld, 2000). Sec-
ondly, several suitable PET radioligands became available relatively
early for studying regional binding of the serotonin transporter in
brain (Brust et al., 1999, 2003; Houle et al., 2000). In a recent study,
Miller and coworkers addressed the issue of whether disturbances
in serotonin transporters provide reliable links between childhood
abuse and subsequent depressive disorders (Miller et al., 2009b).
They re-assessed PET data from an earlier study of adult sub-
jects, in which [11C]McNeil 5652 was used to estimate the binding
potential of serotonin transporters (Parsey et al., 2006a). The sub-
jects were asked about physical and/or sexual abuse during their
lifetime. The present study compared PET data from subjects that
reported childhood abuse and those who reported no such expe-
rience. Binding potentials of serotonin transporters were lower in
several brain regions of depressed subjects who reported child-
hood abuse than in those who reported no such abuse. Miller and
coworkers interpreted their findings in terms of a lower density
of serotonin transporters in depressed subjects who experienced
childhood abuse and speculated that childhood abuse can affect
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the availability of serotonin transporters later in life (Miller et al.,
2009b). We must note, however, that estimates of binding poten-
tials are a composite of three factors, not just the density of receptor
sites. Secondly, there is no way of knowing from their study how
and when differences in the binding potential of serotonin trans-
porters may have taken place. Therefore, their proposals appear
premature and ignore several possibilities, such as differences in
functional properties of serotonin transporters at birth or indi-
vidual differences in effects of the experimental setting on binding
potentials.
Frokjaer et al. (2009) used PET to address the issue of whether
heritability affects central molecular mechanisms that may be
involved in depressive disorders. They used the Danish Twin Reg-
ister and the Danish Psychiatric Central Register to find subjects
for the study. Their “high-risk group” consisted of twins with a
co-twin having a hospital-discharge diagnosis of mood disorder,
whereas their “low-risk group” had twins with a co-twin with
no registered psychiatric diagnosis or personal history of mood
disorder. The ultimate aim of the PET study was to identify indi-
viduals at high-risk of becoming depressed. The binding potential
of serotonin transporters toward [11C]DASB in the dorsolateral
prefrontal cortex was lower in the high-risk group than in the low-
risk group, whereas no other brain regions showed reliable group
differences, and the binding potentials of serotonin transporters
toward [11C]DASB failed to correlate with scores on the Hamilton
depression scale.
Reimold et al. (2011) carried out PET with [11C]DASB in search
of links between the responsiveness of the stress hormone system
and the availability of serotonin transporters in negative mood
states. They studied depressed subjects who were medication-free
before and during the research project. The responsiveness of the
stress hormone system was assessed by measuring plasma cortisol
at times after administration of dexamethasone and corticotrophic
releasing hormone in a modified suppression test (Turner, 1982;
Amsterdam et al., 1983). PET scans and stress tests were carried out
on separate days. Binding of [11C]DASB was reduced in the thala-
mus of depressed patients compared with healthy subjects, which
replicated previous findings (Reimold et al., 2011). High respon-
siveness in the hormone suppression test was correlated with low
binding of thalamic serotonin transporters toward [11C]DASB.
The findings serve to link negative mood states, stress responsive-
ness, and properties of serotonin transporters that are independent
of genotype.
Politis and coworkers used [11C]DASB for PET to study pos-
sible relationships between binding by serotonin transporters and
depressive symptoms in patients with Parkinson disease (Poli-
tis et al., 2010). Rating scales provided measures of depression
severity, and cutoff points enabled classification of the Parkin-
son patients as being either depressed or non-depressed. Regional
binding potentials of serotonin transporters in 12 brain regions
were estimated by a graphical method with cerebellum gray mat-
ter as reference region. A group of healthy, non-depressed subjects
was included in the study, and regional binding potentials of sero-
tonin transporters toward [11C]DASB were compared between
groups. Regional binding potentials were lower in all brain regions
of non-depressed Parkinson patients than in healthy subjects. Sim-
ilarly, the binding potentials for serotonin transporters toward
[11C]DASB were lower in eight brain regions of depressed Parkin-
son patients compared with values for healthy subjects. Thus, low
binding potentials of serotonin transporters were unrelated to the
depression status of Parkinson patients.
Studies of serotonin transporters in depressive disorders can
explore possible relationships between regional binding potentials,
genotype, and symptom severity. At present, two central questions
remain regarding binding potentials of serotonin transporters in
depressive disorders. Firstly, is symptom severity reliably related
to binding potentials? Secondly, is the genotype of serotonin
transporters reliably related to binding potentials?
Murthy and coworkers performed a PET study recently to deter-
mine whether polymorphic variations in the promoter region
of genes coding for the serotonin transporter, so-called S- and
L-alleles (Canli and Lesch, 2007), determine regional binding
potentials of serotonin transporters toward [11C]DASB (Murthy
et al., 2010). They examined seven brain regions and esti-
mated binding potentials by the reference tissue method. As
expected (Houle et al., 2000; Ginovart et al., 2001), highest
binding of [11C]DASB took place in raphe, putamen, amyg-
dala, and thalamus, but binding potentials failed to be reli-
ably related to genotype. That finding agrees with recent evi-
dence (Reimold et al., 2011) that opposes the notion of direct
causal connections between genotype and functional proper-
ties of serotonin transporters in depressive disorders (Collier
et al., 1996; Mann et al., 2000; Homberg and Lesch, 2011).
In addition, most studies find that symptom severity fails to
correlate reliably with regional binding potentials of serotonin
transporters toward [11C]DASB in depressed subjects (Frokjaer
et al., 2009; Smith and Jakobsen, 2009; Politis et al., 2010). Thus,
regional binding potentials of serotonin transporters can vary
independent of genotype and of symptom severity in depressive
disorders.
Laje et al. (2010) also used PET to look for links between PET
findings on serotonin transporters and genotype, with focus on
serotonin type 2A receptors. Their study was motivated by the
outcome of a previous report on relationships between a single
genotype of serotonin type 2A receptors (rs7997012) and clinical
antidepressant effects of citalopram, a selective serotonin reuptake
inhibitor (McMahon et al., 2006). In their recent study, Laje and
coworkers determined whether binding potentials of [11C]DASB
in several brain regions were reliably related to any of fourteen sin-
gle nucleotide polymorphisms of serotonin type 2A receptors in
depressed outpatients and healthy controls. The data of depressed
patients and healthy volunteers were pooled in order to increase
statistical power, on the assumption of no difference between
diagnostic subgroups for whatever association may exist between
genetic markers (genotypes) and binding potentials (phenotypes).
As a result, the findings cannot indicate whether there were any
reliable differences between properties of serotonin transporters
in depressed versus non-depressed subjects. Special procedures,
most of which are unfamiliar to the present authors, were used
in the data analysis to adjust for multiple correlated compar-
isons. Binding potentials of [11C]DASB by serotonin transporters
in thalamus and insula were associated with one genetic variant
of serotonin type 2A receptors (rs7333412). Laje and coworkers
proposed that genetic variation in serotonin type 2A receptors
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and either functional aspects of serotonin transporters or central
serotonergic transmission affect the therapeutic response to drug-
induced inhibition of serotonin transport in major depression,
although their findings provided no direct empirical evidence for
such claims.
SEROTONIN TYPE 1A RECEPTOR
Miller et al. (2009a) determined whether binding of [11C]WAY-
100635 by serotonin type 1A receptors differs between healthy
subjects, depressed patients, and depressive patients in remis-
sion. Their previous work had shown an increase in serotonin
type 1A receptor binding in depressed patients (Parsey et al.,
2006b), and the new study contained a replication attempt. None
of the subjects had taken antidepressant medication for at least
6 months before PET scanning. Miller and coworkers performed
PET with [11C]WAY-100635 to test the notion that elevated bind-
ing potentials are a molecular trait of depressive disorders. Careful
diagnostic procedures and strict inclusion criteria were applied for
selection of subjects. In addition, particular attention was given to
the method for estimating binding potential, in light of discrep-
ancies and controversies in previous studies (Bhagwagar et al.,
2004; Parsey et al., 2006b; Moller et al., 2007; Hirvonen et al.,
2008). Binding potentials of serotonin type 1A receptors toward
[11C]WAY-100635 were, once again, higher in remitted depressed
subjects and currently depressed subjects compared with healthy
subjects. However, the estimates of binding potentials depended
heavily on the region used as reference tissue; cerebellar white mat-
ter gave higher values for binding potentials of serotonin type 1A
receptors in remitted patients than in healthy subjects, whereas
cerebellar gray matter produced opposite results. Such findings
suggest, surprisingly, that an important key to understanding the
impact of serotonin type 1A receptors in depressive disorders
resides in differences between the white and gray matter of the
cerebellum.
Sullivan and coworkers studied binding of [11C]WAY-100635
in medication-free patients with bipolar depressive disorder com-
pared with never-depressed, healthy subjects (Sullivan et al., 2009).
A major thrust of this study concerned comparisons between
methods for estimating the binding potential of serotonin type
1A receptors toward the PET radioligand. They included arter-
ial blood sampling with analysis of metabolites and free plasma
fraction for estimates of binding potentials of regional serotonin
type 1A receptors. In addition, estimates of binding potentials
were obtained by a reference region method, and the serotonin
type 1A gene was genotyped to see whether genetic factors affect
5-HT1A binding in bipolar disorder. Values for regional bind-
ing potentials of serotonin type 1A receptors toward [11C]WAY-
100635 were log transformed, and statistical analysis was then
carried out by a linear mixed-effects model. Estimates of regional
binding potentials, based on plasma data, were higher in bipolar
depressed patients than in never-depressed subjects, due mainly
to relatively high values in depressed, bipolar males, along with
lower free plasma fractions in depressed, bipolar subjects com-
pared with never-depressed subjects. It is noteworthy that values
for regional binding potentials of serotonin type 1A receptors
toward [11C]WAY-100635 failed to correlate reliably with the clin-
ical condition of subjects, and no reliable relationships were noted
between diagnostic groups for [11C]WAY-100635 binding and C(-
1019)G promoter polymorphisms. Similarly, estimates of binding
potentials by a reference region method provided no reliable dif-
ference between bipolar depressed patients and never-depressed
subjects.
Parsey et al. (2010) carried out another PET study with
[11C]WAY-100635 to examine possible sources of discrepancies in
previous studies concerning whether regional binding potentials
of serotonin type 1A receptors are higher or lower in major depres-
sive disorders than in non-depressed subjects. As noted above
(Sullivan et al., 2009), regional binding potentials of serotonin type
1A receptors toward [11C]WAY-100635 were reduced in depressed
subjects compared with non-depressed subjects when reference
tissue was cerebellar gray matter, whereas opposite findings were
obtained with the use of cerebellar white matter as reference tis-
sue. The marked sensitivity of estimates of radioligand binding by
serotonin type 1A receptors on selection of cerebellar tissue com-
plicates the use and interpretation of reference region methods for
PET studies of depression with [11C]WAY-100635.
Karlsson and coworkers determined whether the binding
potential of serotonin type 1A receptors is affected by psychother-
apy and/or antidepressant drug treatment (Karlsson et al., 2010).
Using a randomized design, they treated depressed subjects from
a previous PET study (Hirvonen et al., 2008) with either fluox-
etine or short-term psychodynamic therapy. Brain imaging with
[11C]WAY-100635 was done before and after treatment, along with
symptom assessment by the Hamilton Depression Rating Scale.
They used the reference region method based on cerebellar white
matter and found increased binding potentials of serotonin type
1A receptors toward [11C]WAY-100635 in cortical regions in the
group given psychotherapy compared with those given fluoxetine,
despite the fact that improvement of depression was similar in
the two groups. Compared with healthy subjects, post-treatment
binding potentials of serotonin type 1A receptors were elevated in
the psychotherapy group but not in the fluoxetine group. Karlsson
and coworkers view their findings as direct evidence for a spe-
cific neurotransmitter mechanism involved in the neurobiology
of psychotherapy, perhaps unrelated to therapeutic response.
Saijo et al. (2010a) did a study to see whether antidepres-
sant treatment affects the binding potential of serotonin type 1A
receptors. In their case, the antidepressant treatment consisted
of electroconvulsive therapy (ECT). Using PET with [11C]WAY-
100635, brain imaging took place before and after ECT in a
group of depressed inpatients. Kinetic data analysis was car-
ried out using the reference region method based on cerebellar
gray matter. Never-depressed subjects underwent PET scanning
with [11C]WAY-100635 on one occasion to provide measures of
regional binding by serotonin type 1A receptors for compari-
son with values in depressed inpatients. The patients continued
to receive selective serotonin reuptake inhibitors during ECT.
Depression improved markedly in all patients given ECT between
the first and second PET scans, but no reliable changes occurred in
regional binding potentials of serotonin type 1A receptors. Com-
pared with never-depressed subjects, reduced binding potentials
of serotonin type 1A receptors were noted in the midbrain raphe
region both before and after completion of antidepressant ther-
apy. The findings agree with a previous report on the lack of direct
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relationships between binding by serotonin type 1A receptors and
negative mood state (Bhagwagar et al., 2004).
Lanzenberger et al. (2013) also determined by PET whether
ECT alters [11C]WAY-100635 binding in brain regions. They
scanned treatment-resistant depressed patients twice before ECT
begun, so as to establish the test-retest validity of the procedure
and, thereby, to improve the initial characterization of serotonin
type 1A receptors. The patients remained in steady-state drug
treatment during the study. Cerebellar gray matter, excluding the
vermis, served as reference tissue for estimating the binding poten-
tial of serotonin type 1A receptors. ECT lowered the binding
potential of serotonin type 1A receptors toward [11C]WAY-100635
throughout the brain,without region-specific effects. Of particular
importance for the present review is the fact that no reliable corre-
lations were noted between the magnitude of treatment-induced
changes in radioligand binding by serotonin type 1A receptors and
changes in scores on the Hamilton depression scale.
Theodore et al. (2007, 2012) followed-up a previous PET study
on possible dysfunctions of serotonin type 1A receptors in depres-
sive disorders in patients with temporal epilepsy. In their new
study, they looked for relationships between the binding potential
of hippocampal serotonin type 1A receptors toward [11C]WAY-
100635 and depression in epileptic patients. They used metabolite-
corrected plasma input functions in their estimates of binding
potentials, and found that high scores on the Beck depression self-
rating inventory were correlated with low hippocampal binding
of [11C]WAY-100635 in the hemisphere on the side of the seizure
focus. We can only wonder about the potential clinical importance
of these findings, while we wait for them to be replicated to judge
their validity.
A major controversy in PET studies of serotonin type 1A
receptors currently centers around differences noted between
studies of regional binding of [11C]WAY-100635 in depression
(Shrestha et al., 2012). Uncertainties may stem from a range of
factors, including choice of reference region, measurement of
radiometabolites, altered affinity state of receptors, and relatively
small samples (Shrestha et al., 2012). There is, nonetheless, gen-
eral agreement that published findings fail to demonstrate reliable
relationships between the severity of depression and [11C]WAY-
100635 binding. That situation in itself casts doubt on the notion
that PET studies of serotonin type 1A receptors can disclose the
neurobiological basis of depressive disorders. In view of radiation
doses received by subjects in PET studies along with the relatively
great expense of such studies, perhaps the time has come to aban-
don the apparently futile search for confirmatory evidence that
regional binding potentials of serotonin type 1A receptors toward
[11C]WAY-100635 are critical for the course of psychic depression.
SEROTONIN TYPE 1B RECEPTOR
Murrough and coworkers carried out the first PET study on sero-
tonin type 1B receptors in depressive disorders (Murrough et al.,
2011). They estimated the binding potential of [11C]P943 (Nabulsi
et al., 2010) in brain regions rich in serotonin type 1B receptors,
namely ventral striatum and ventral globus pallidus (Sari, 2004).
The study used healthy subjects and medication-free subjects in
prolonged episodes of major depressive disorder. Kinetic data
analysis consisted of a multiple reference tissue method (Ichise
et al., 2003) with cerebellum as reference region. PET data were
expressed as the ratio between binding potentials of serotonin type
1B receptors in ventral striatum versus ventral globus pallidus.
That ratio was markedly lower in both hemispheres of subjects
with major depressive disorder than in healthy subjects, but it
failed to correlate with clinical or demographic items. In addition,
we wish to point out that presenting PET data only as ratios pre-
cludes gaining an understanding of the neuromolecular source of
the alleged differences between healthy and depressed subjects in
receptor binding in brain regions.
SEROTONIN TYPE 2 RECEPTOR
Yatham and coworkers examined the status of serotonin type
2 receptors before and after a series of right unilateral ECT in
depressed subjects who were refractory to previous antidepres-
sant therapies (Yatham et al., 2010). Needless to say, ECT provides
one of the most powerful antidepressant procedures by which
to explore possible relationships between depression severity and
neuroreceptor binding (Minichino et al., 2012). The number of
ECTs administered to each depressed subject was based on clini-
cal response, with a maximum of eight treatments. Psychotropic
drugs other than benzodiazepines for sleep were discontinued at
least 1 week prior to PET scanning with [18F]setoperone. Estimates
of the binding potential of serotonin type 2 receptors in the cere-
bral cortex toward [18F]setoperone were obtained by a graphical
reference tissue method. Depressed subjects who were included in
this study had relatively high scores on the Hamilton depression
rating scale, indicative of their severe condition. Binding potentials
of serotonin type 2 receptors in several cortical regions, including
medial prefrontal cortex and parahippocampal gyri, were lower
after ECT than before treatment, but the magnitude of clinical
improvement failed to correlate reliably with changes in binding
potentials.
The lack of a reliable relationship between the clinical con-
dition of depressed patients given ECT and regional binding
of [18F]setoperone by serotonin type 2 receptors challenges the
notion of causal links between depressive disorders and that
receptor system.
DOPAMINE D2/3 RECEPTOR
Saijo et al. (2010b) used [11C]FLB 457 for PET to determine
whether ECT affects the binding of extrastriatal dopamine D2/3
receptors in depressed subjects. They carried out PET scanning
before and after ECT in depressed patients who were allowed to
continue taking antidepressant medication during the study. A
group of never-depressed, healthy subjects were included in the
study; they were scanned once in order to obtain baseline esti-
mates of binding of [11C]FLB 457 by dopamine D2/3 receptors for
comparison with depressed inpatients. ECT reduced the severity
of depression in all patients, but binding potentials of dopamine
D2/3 receptors toward [11C]FLB 457 in patients failed to be reliably
related to improvement in their clinical condition. Binding poten-
tials of dopamine D2/3 receptors toward [11C]FLB 457 were lower
in right anterior cingulate after ECT than before treatment, but
no reliable differences were noted between depressed patients and
never-depressed subjects.
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Normalized parametric images were used by Saijo and cowork-
ers in their analysis of dopamine D2/3 receptor binding. That
procedure fails, however, to provide quantitative estimates for
statistical comparisons. Nevertheless, it is noteworthy once again
that the clinical condition of depressed subjects was unrelated to
[11C]FLB 457 binding by dopamine D2/3 receptors.
MULTIPLE MONOAMINE RECEPTORS
Smith and coworkers radiolabeled mirtazapine, a multitarget anti-
depressant compound (Millan, 2006, 2009), for PET in treatment-
resistant, medication-free, depressed subjects, and in never-
depressed, healthy subjects (Smith et al., 2009). The rationale for
the study centered on the notion that treatment-resistant depres-
sion may involve dysfunction of several neuroreceptor systems
that may be assessed simultaneously by a multitarget PET radi-
oligand. Binding potentials of receptors toward [11C]mirtazapine
were lower in cortical regions of treatment-resistant, depressed
subjects than in healthy subjects, and depression scores were cor-
related inversely with binding potentials in frontal, temporal,
and occipital cortical regions. However, the multiple pharma-
cological actions of [11C]mirtazapine on central receptor sys-
tems preclude statements on the relative role of specific neuro-
molecular mechanisms in differences detected by PET between
depressed and healthy subjects. Another drawback of the study
concerns differences in the specific activity of the radioligand
administered to healthy versus depressed subjects. That factor
was dealt with by post hoc regression analysis, which is a pro-
cedure with many pitfalls (Vul et al., 2009; Simmons et al.,
2011).
MONOAMINE OXIDASE TYPE A
Meyer and coworkers explored possible relationships between
depressive disorders and regional binding of [11C]harmine, a PET
radioligand for studying monoamine oxidase type A (Meyer et al.,
2009a). They determined whether therapeutic effects of anti-
depressant drug treatment affects binding of [11C]harmine by
monoamine oxidase type A, and whether recurrence of depres-
sion is associated with the level of [11C]harmine binding in brain
regions. To determined whether successful treatment with an anti-
depressant drug affects central binding of [11C]harmine, they PET
scanned depressed subjects twice, once before treatment, and again
after 6 weeks of treatment with a selective serotonin reuptake
inhibitor. It is noteworthy for the present review that beneficial
clinical effects of antidepressant treatment failed to reliably affect
regional binding of [11C]harmine in the brain. Some relation-
ships were noted, nevertheless, between binding of [11C]harmine
and depression. For example, [11C]harmine binding was elevated
in brain regions of depressed subjects and of subjects who had
recovered from depression compared with never-depressed sub-
jects, and recurrence of depression was associated with elevated
[11C]harmine binding.
This study was carried out with meticulous attention to detail
in screening subjects, scanning procedures, and kinetic data analy-
sis. In our view, the failure of beneficial antidepressant treatment
to affect [11C]harmine binding as measured by PET dissociates
depressive psychopathology from central levels of monoamine oxi-
dase type A. The relationship reported between elevated activity
of monoamine oxidase type A in some brain regions and recur-
rence of depression was statistically significant without correction
for multiple comparisons, but inspection of the data indicates
marked overlap between groups, which tends to call that finding
into question.
NON-MONOAMINERGIC MECHANISMS
MUSCARINIC TYPE 2 RECEPTOR
Cholinergic neurotransmission has a widespread distribution in
the brain and the parasympathetic nervous system (Mineur and
Picciotto, 2010; Wevers, 2011). Cannon and coworkers combined
PET brain imaging and genotyping in their study of central cholin-
ergic processes in depressive disorders (Cannon et al., 2011). They
assessed possible relationships between six single nucleotide poly-
morphisms of the cholinergic muscarinic type 2 receptor gene
and binding of the high-affinity cholinergic agonist, [18F]FP-TZT.
Their study had several strong points. For example, they included
an independent test of a previous finding (Cannon et al., 2006),
applied strict exclusion criteria with regard to the use of nicotine
and psychotropic drugs by their subjects, and used appropriate
statistical procedures with corrections for multiple comparisons
(Curran-Everett, 2000; Nieuwenhuis et al., 2011). They found that
differences in the degree of binding of [18F]FP-TZTP in the ante-
rior cingulate cortex of bipolar depressive versus healthy subjects
depended on the allelic composition of the single nucleotide poly-
morphism (rs324650), whereas no such differences were noted
for [18F]FP-TZTP binding between healthy subjects and subjects
with unipolar depressive disorder. Cannon and coworkers inter-
preted their finding of relatively low [18F]FP-TZTP binding in
bipolar disorder in relation to the nucleotide sequence coding for
the muscarinic type 2 receptor. In our view, that is a truly bold
hypothesis on the basis of a single study.
NICOTINIC RECEPTOR
Nicotinic receptors contribute to central molecular mechanisms
ranging from nicotine dependence to severe cognitive dysfunction
(Dani and Bertrand, 2007; Romanelli et al., 2007). Meyer et al.
(2009b) reasoned that disturbances in nicotinic receptors may
contribute to symptoms of depression in patients with Parkinson
disease. To test that notion, they carried out PET with [18F]FA-
85380 in Parkinson patients and healthy subjects. All subjects
were non-smokers, which ruled out nicotine dependence as a
confounding factor (Brody et al., 2006). Depression in Parkin-
son patients was determined by a self-report questionnaire, and
PET data were analyzed by region-of-interest and voxel-based
procedures. As expected (Perry et al., 1995), binding by nico-
tinic receptors was reduced in several brain regions of Parkinson
patients compared with healthy subjects. In addition, depression
scores in Parkinson patients were correlated inversely with binding
of [18F]FA-85380 in several brain regions. Meyer and coworkers
speculated that their PET procedures may enable early detection
of nicotinic alterations in brain regions of Parkinson patients at
risk of developing depressive disorders.
GAMMA AMINO BUTYRIC ACID (GABA) TYPE A RECEPTOR
GABAergic mechanisms are currently receiving much attention
in research on psychic disorders (Rudolph and Knoflach, 2011).
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Klumpers and coworkers used [11C]flumazenil for PET to see
whether binding of central GABAA receptors differs between
depressed and healthy subjects (Klumpers et al., 2010). In addition,
they determined whether antidepressant drug treatment affects
GABAA receptor binding. The findings depended heavily on the
method used for PET data analysis. Voxel-based data analysis indi-
cated that antidepressant drug treatment reduced [11C]flumazenil
binding in right lateral temporal gyrus and dorsolateral prefrontal
cortex of depressed patients. In contrast, region-of-interest analy-
sis revealed no reliable differences of antidepressant treatment
on [11C]flumazenil binding, no differences in [11C]flumazenil
binding between depressed and healthy subjects, and no reli-
able correlations between regional receptor binding potentials and
depression scores. In a selected sample of patients, a relation-
ship was found between reduced binding of [11C]flumazenil at
certain brain sites and lack of neuroendocrine suppression in a
dexamethasone-suppression test. Klumpers and coworkers inter-
preted their findings in terms of putative deficiencies in inhibitory
GABAergic mechanisms.
PHOSPHODIESTERASE TYPE 4
Fujita and coworkers used [11C]-(R)-rolipram for PET to probe
the cAMP second messenger system in healthy subjects and
depressed patients (Fujita et al., 2012). Rolipram was originally
developed as an antidepressant drug to inhibit phosphodiesterase
type 4 and thereby reduce metabolism of cAMP (Wachtel, 1982,
1983; Zanotti-Fregonara et al., 2011). As usual (Gjedde et al., 2005),
estimates of radioligand binding in brain regions depended on the
density and the activity of the enzyme, as well as the concentra-
tion of other compounds that compete at the receptor site. Fujita
and coworkers found that [11C]-(R)-rolipram binding was reliably
lower throughout the brain of depressed patients than in healthy
subjects, with no reliable correlations between radioligand binding
and the severity of depressive symptoms.
AMYLOID AND TAU PROTEINS
Pathological changes in the brain consisting of amyloid plaques
and neurofibrillar tangles typically herald cognitive disturbances
in Alzheimer disease (Vardy et al., 2006; Golde et al., 2010; Small
et al., 2012). Lavretsky et al. (2009) used [18F]DDNP to see whether
amyloid plaques and neurofibrillar tangles are also present in the
brain of middle-aged and older subjects with mild-to-moderate
depressive disorders, with and without mild cognitive impairment.
None of the subjects had required antidepressant drug treatment.
Depressive symptoms in subjects with mild cognitive impairment
were associated with increased binding of [18F]DDNP in lateral
temporal regions, whereas symptoms of depression in subjects
without mild cognitive impairment were associated with increased
binding of [18F]DDNP in medial temporal regions. Thus, amyloid
plaques and neurofibrillar tangles were identified by PET in elderly,
mildly depressed subjects, regardless of their cognitive condition.
Kumar and coworkers also used [18F]DDNP for PET to
explore possible links between depressive disorders and amyloid
plaques and neurofibrillar tangles (Kumar et al., 2011). They
recruited non-demented subjects with late-life depression, and
compared them to non-depressed, age-matched subjects. Bind-
ing of [18F]DDNP in several cortical brain regions was higher
in the group with late-life depression than in the age-matched,
non-depressed group.
P-GLYCOPROTEIN
The blood-brain barrier limits the bi-directional passage of mol-
ecules, while the removal of certain molecules from the brain
is enhanced by the P-glycoprotein efflux pump. Verapamil is a
calcium channel blocker that is removed from the brain by the
P-glycoprotein pump, and the drug can be radiolabeled with a
positron-emitting nuclide and used to study the P-glycoprotein
pump (Bartels et al., 2010). de Klerk et al. (2009) examined possi-
ble relationships between the P-glycoprotein pump and depressive
disorders. They used [11C]verapamil for PET brain imaging in
a group of severely depressed subjects receiving various antide-
pressant drugs and in a group of non-depressed, unmedicated
subjects. The binding of [11C]verapamil in the whole brain failed
to differ reliably between groups, while regional data analysis indi-
cated that levels of [11C]verapamil were lower in prefrontal cortex
and temporal lobes of depressed subjects than in healthy controls.
de Klerk and coworkers interpreted their finding in relation to the
possible impact of long-term usage of antidepressant drugs and/or
treatment-resistant depression on the P-glycoprotein pump.
The diversity of recent PET studies on non-monoaminergic
mechanisms in depressive disorders precludes general statements
concerning the findings. [18F]DDNP was used in two recent
studies that found an association between binding by amyloid
plaques and neurofibrillar tangles in temporal lobes of elderly
subjects with mild-to-moderate depression. That finding con-
curs with reports on neuropathology in temporal cortex of
depressed subjects (Saylam et al., 2006; Vasic et al., 2008) and
supports the well-known relationship between depressive disor-
ders and Alzheimer’s disease (Caraci et al., 2010; Frisardi et al.,
2011). Cholinergic mechanisms have also been implicated in
both depressive disorders and Alzheimer’s disease (Mineur and
Picciotto, 2010; Fisher, 2012), which may relate to the differ-
ences observed in binding of [18F]FP-TZTP and [18F]FA-85380
between healthy subjects and subjects with depressive disorders.
With regard to GABAergic neurotransmission, much evidence
implicates disturbances of function in depression as well as other
neuropsychiatric disorders (Rudolph and Knoflach, 2011). The
recent PET findings with [11C]flumazenil are of interest in that
respect (Klumpers et al., 2010), despite the fact that benefi-
cial effects of antidepressant treatment were associated with a
further reduction of radioligand binding. Obviously, we have
much to learn regarding whether non-monoaminergic mecha-
nisms can be reliably linked with depressive disorders by PET brain
imaging.
GENERAL DISCUSSION
The search continues for PET radioligands that can disclose causal
links between the binding properties of central neuromolecular
processes and the clinical condition of people suffering from
depressive disorders. Our account of PET findings presented in
this review is both critical and harsh, based on our serious con-
cern regarding the current lack of clear-cut relationships between
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neuromolecular processes as measured by PET and changes in the
severity of depression. In particular, beneficial effects of potent
antidepressant treatments have typically failed to affect neurore-
ceptor binding of PET radioligands in subjects who were depressed
at the start of the study, but who experienced clear-cut reductions
in symptom severity. We are aware that lack of effect of beneficial
antidepressant treatment on receptor binding in depressed sub-
jects can be said to reflect a so-called “trait variable,” but we fail to
see the value of that notion since it has no impact on treatment
strategy. What is more, the notion of a “trait variable” as a stable,
neuromolecular abnormality fails to take into account the possi-
bility that the foreign experience of being constrained in a PET
scanner and having a radioactive substance injected into a vein
may affect brain function differently in depressed subjects than
in healthy volunteers. If that were to occur, then the PET find-
ings would reflect a so-called “state variable” rather than a “trait
variable.”
The failure of changes in the clinical condition of depressed
subjects to be reliably linked with changes in binding of PET
radioligands in the living brain adds to the disappointment that
currently surrounds the field (Jones and Rabiner, 2012). Sadly,
studies carried out by PET with available radioligands have neither
proved nor refuted conclusively any hypothesis concerning causal
connections between molecular neurobiology and the severity
of depression. The failure of PET to demonstrate reliable effects
on neuroreceptors in depressed subjects receiving potent antide-
pressant treatments may indicate that neuronal systems probed
by currently available positron-emitting radioligands are remark-
ably stable. If so, then the success of PET scanning in detecting
causal relationships between symptoms of depression and molec-
ular neurobiology may require the invention of further positron-
emitting radioligands along with new scanning procedures that
can detect dynamic variations in neuromolecular processes that
remain unknown. The richness of human emotions, thoughts, and
actions, plus the complexity of molecular events in the human
brain, caution against expecting PET brain imaging to provide
rapid progress toward improving the treatment of depressive
disorders.
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